Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patients

被引：0

作者：

Yilmaz, Yigit ^{[1
]}

Ozercan, Mesut Melih ^{[2
]}

Ancin, Burcu ^{[2
,3
]}

Dikmen, Zeliha Gunnur ^{[4
]}

Tuncali, Meltem Caglar ^{[5
]}

Tuncel, Murat ^{[5
]}

Uysal, Serkan ^{[2
]}

Kumbasar, Ulas ^{[2
]}

Dikmen, Erkan ^{[2
]}

Dogan, Riza ^{[2
]}

机构：

[1] Ankara Private Guven Hosp, Dept Thorac Surg, Ankara, Turkiye

[2] Kirikkale Univ, Fac Med, Dept Thorac Surg, Kirikkale, Turkiye

[3] Burdur State Hosp, Dept Thorac Surg, Burdur, Turkiye

[4] Hacettepe Univ, Fac Med, Dept Clin Biochem, Ankara, Turkiye

[5] Hacettepe Univ, Fac Med, Dept Nucl Med, Ankara, Turkiye

来源：

BIOMARKERS IN MEDICINE | 2025年

关键词：

Human epididymis protein 4 (HE4); lung cancer; positron emission tomography (PET); standard uptake value (SUV); metabolic tumor volume (MTV); total lesion glycolysis (TLG); EPIDIDYMIS PROTEIN 4; TOTAL LESION GLYCOLYSIS; PROGNOSTIC VALUE; SERUM HE-4; FOLLOW-UP; METASTASIS; EXPRESSION; DIAGNOSIS; CA125;

D O I：

10.1080/17520363.2025.2471744

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Aim: To investigate the relationship between serum human epididymis protein 4 (HE4) levels and metabolic parameters of positron emission tomography (PET) imaging in patients with lung cancer. Methods: Sixty non-small cell lung cancer (NSCLC) patients were included in this prospective study. Demographic information, smoking status, comorbid pathologies, preoperative HE4 levels, PET imaging metabolic parameters, disease stage and histopathology were recorded. Results: Significant positive correlations between serum HE4 levels and all the metabolic parameters were observed (p < 0.05). In univariate regression analyses, it was observed that high serum HE4 levels could indicate tumor be squamous cell carcinoma (SCC) (p = 0.029), advanced T stage (p = 0.041), and have high maximum standart uptake value (SUVmax) (p = 0.017). Conclusion: Serum HE4 levels can be used as a biomarker to predict tumor burden and metabolic activity for NSCLC patients. Although sufficient per power analysis, this study may have benefited from further expansion, and by patient heterogeneity in TNM stage and tumor histology, potentially affecting the assessment of parameter relationships.

引用

页码：259 / 265

页数：7

共 32 条

[11]

Lamy P.J., Plassot C., Pujol J.L., Serum HE4: an independent prognostic factor in non-small cell lung cancer, PLOS ONE, 10, 6, (2015)

[12]

Huang W., Wu S., Lin Z., Et al., Evaluation of HE4 in the diagnosis and follow up of non-small cell lung cancers, Clin Lab, 63, 3, pp. 461-467, (2017)

[13]

Detterbeck F.C., Boffa D.J., Kim A.W., Et al., The eighth edition lung cancer stage classification, Chest, 151, 1, pp. 193-203, (2017)

[14]

Steinert H.C., PET and PET-CT of lung cancer, Methods Mol Biol, 727, pp. 33-51, (2011)

[15]

Kuzdzal J., Asamura F., Goldstraw P., Et al., (2014)

[16]

Balci T., Komek H., Akciğer kanserinin tanı ve takibinde nükleer tıp. (Translation: nuclear medicine in the diagnosis and follow-up of lung cancer), 8, pp. 67-83, (2017)

[17]

Im H.J., Pak K., Cheon G.J., Et al., Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis, Eur J Nucl Med Mol Imaging, 42, 2, pp. 241-251, (2015)

[18]

Liu J., Dong M., Sun X., Et al., Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: A meta-analysis, PLOS ONE, 11, 1, (2016)

[19]

Zhu D., Ma T., Niu Z., Et al., Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer, Lung Cancer, 73, 3, pp. 332-337, (2011)

[20]

Wen W., Piao Y., Xu D., Et al., Prognostic value of MTV and TLG of (18)F-FDG PET in patients with stage I and II non-small-cell lung cancer: a meta-analysis, Contrast Media Mol Imaging, 2021, (2021)

← 1 2 3 4 →